Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 6/2016

Open Access 01-12-2016 | Secondary Causes of Osteoporosis (SJ Warden, Section Editor)

Lower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysis

Authors: Lucia Gomez, Brendon Stubbs, Ayala Shirazi, Davy Vancampfort, Fiona Gaughran, John Lally

Published in: Current Osteoporosis Reports | Issue 6/2016

Login to get access

Abstract

It remains unclear if differences in bone mineral density (BMD) exist at different skeletal sites between people with schizophrenia and age- and sex-matched healthy controls (HCs). Major databases were searched from inception until February 2016 for studies measuring BMD using dual-energy X-ray absorptiometry (DXA) at any skeletal site in individuals with schizophrenia. Ten studies investigating 827 people with schizophrenia (55.4 % female, 33.8 ± 9.7 years) and 1379 HCs (58.7 % female, 34.7 ± 9.1 years) were included. People with schizophrenia had significantly reduced BMD at the lumbar spine (standardised mean difference adjusted for publication bias (SMD) = −0.950 (95 % CI = −1.23 to −0.66, fail-safe number = 825) and hip (SMD = −0.534, 95 % CI = −0.876 to −0.192, fail-safe number = 186). A higher proportion of hyperprolactinaemia (β = −0.0102, p < 0.0001) and smokers (β = −0.0099, p = 0.02) moderated a larger reduced BMD at the lumbar spine. Further research is required to investigate if low bone mass and fractures can be prevented in people with schizophrenia.
Literature
1.
Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–36.CrossRefPubMed
2.
Cooper C, Campion G, Melton III L. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–9.CrossRefPubMed
3.
Riggs BL, Melton LR. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17(5):S505–11.CrossRef
4.••
Stubbs B et al. A meta‐analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130(6):470–86. This study identifies an increased prevalence of osteoporosis in people with shizophrenia and highlights potential risk factors for this group.CrossRefPubMed
5.
Halbreich U et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57(5):485–91.CrossRefPubMed
6.
De Hert M, Detraux J, Stubbs B. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opinion on Drug Safety, 2016 (in press)
7.
Stubbs B et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126–33.CrossRefPubMed
8.•
Wu C-S et al. Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: a 10-year population-based case–control study. J Clin Psychol. 2015;76(9):1478–223. An investigation into the association between antipsychotic medication and risk of hip fracture in patients with schizophrenia.
9.
Naidoo U, Goff D, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology. 2003;28:97–108.CrossRefPubMed
10.
Lally J et al. Clinical correlates of vitamin D deficiency in established psychosis. BMC Psychiatry. 2016;16(1):1.CrossRef
11.•
Crews M et al. Vitamin D deficiency in first episode psychosis: a case–control study. Schizophr Res. 2013;150(2):533–7. This paper identifies low levels of vitamin D in unmedicated patients with first episode psychosis.CrossRefPubMed
12.
Fraser L-A et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450–2.CrossRefPubMed
13.••
Menendez ME et al. Do psychiatric comorbidities influence inpatient death, adverse events, and discharge after lower extremity fractures? Clin Orthop Relat Res. 2013;471(10):3336–48. A discussion of the increased negative impact of fractures on patients with schizophrenia.CrossRefPubMedPubMedCentral
14.
Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190(2):129–34.CrossRefPubMed
15.
Tseng P-T et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine. 2015;94(47), e1967.CrossRefPubMedPubMedCentral
16.
Stroup DF et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.CrossRefPubMed
17.
Moher D et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRefPubMed
18.
DSM-IV, A.P.A.T.F.o. DSM-IV draft criteria. 1993: Amer Psychiatric Pub Incorporated
19.
WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
20.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.CrossRefPubMedPubMedCentral
21.
Wyszogrodzka-Kucharska A, Rabe-Jabłońska J. Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics. Psychiatr Pol. 2004;39(6):1173–84.
22.
Doknic M et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246–54.CrossRefPubMed
23.
Van Der Leeuw C et al. Bone mineral density as a marker of cumulative endogenous estrogen exposure: Relationship to background genetic risk of psychotic disorder. Schizophr Res. 2013;143(1):25–31.CrossRefPubMed
24.
Bolton JM et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31(1):56–60.CrossRefPubMed
25.
Taal MW et al. Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Nephrol Dial Transplant. 1999;14(8):1917–21.CrossRefPubMed
26.
Stewart A, Kumar V, Reid DM. Long‐term fracture prediction by DXA and QUS: a 10‐year prospective study. J Bone Miner Res. 2006;21(3):413–8.CrossRefPubMed
27.
28.
Hummer M, et al. Osteoporosis in patients with schizophrenia. American Journal of Psychiatry. 2005
29.
30.
Wyszogrodzka-Kucharska A, Kunert-Radek J, Rabe-Jabłońska J. Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics—risperidone and olanzapine. Psychiatr Pol. 2004;39(6):1143–55.
31.
Cohen J. Statistical power analysis. Curr Dir Psychol Sci. 1992;1(3):98–101.CrossRef
32.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994:1088–1101
33.
34.
Duval S, Tweedie R. Trim and fill: a simple funnel‐plot-based method of testing and adjusting for publication bias in meta‐analysis. Biometrics. 2000;56(2):455–63.CrossRefPubMed
35.
Wang M et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12‐month prospective study. Hum Psychopharmacol Clin Exp. 2014;29(2):183–9.CrossRef
36.
Maric N et al. Cumulative exposure to estrogen and psychosis: a peak bone mass, case–control study in first-episode psychosis. Schizophr Res. 2005;73(2–3):351–5.CrossRefPubMed
37.
Koçer E. Comparison of bone mineral density levels in young-adult patients with schizophrenia and healthy controls. Düşünen Adam: The Journal of Psychiatry and Neurological Sciences. 2011;24(4):314–20.CrossRef
38.
Jung D-U et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31(4):406–10.CrossRefPubMed
39.
Jung D-U et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391–6.CrossRefPubMed
40.
Bilici M et al. The effect of chronic use of antipsychotics on the bone, breast and cervix. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2011;21(2):114–21.CrossRef
41.
Bilici M et al. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci. 2002;112(7):817–28.CrossRefPubMed
42.
Altındağ Ö et al. Bone mineral density in schizophrenia patients on antipsychotics. KLINIK PSIKOFARMAKOLOJI BULTENI-Bulletin of Clinical Psychopharmacology. 2009;19(4):402–6.
43.
Bergemann N et al. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38(08):1195–201.CrossRefPubMed
44.
45.
46.
Kishimoto T et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):1478–391.CrossRef
47.
Eriksen E, Glerup H. Pathogenesis of osteoporosis. In: Management of fractures in severely osteoporotic bone. Springer; 2000. pp. 13–32
48.
Suzuki N, Ogikubo O, Hansson T. The prognosis for pain, disability, activities of daily living and quality of life after an acute osteoporotic vertebral body fracture: its relation to fracture level, type of fracture and grade of fracture deformation. Eur Spine J. 2009;18(1):77–88.CrossRefPubMed
49.•
Wong CC, McGirt MJ. Vertebral compression fractures: a review of current management and multimodal therapy. J Multidiscip Healthc. 2013;6:205–14. A review of multidisciplinary treatment plans for vertebral fractures.PubMedPubMedCentral
50.
Stubbs B et al. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015;156(11):2121–31.CrossRefPubMed
51.
Stubbs B, Zapata-Bravo E, Haw C. Screening for osteoporosis: a survey of older psychiatric inpatients at a tertiary referral centre. Int Psychogeriatr. 2009;21(01):180–6.CrossRefPubMed
52.
de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2):135–57.CrossRefPubMed
53.
Gardner-Sood P et al. Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med. 2015;45(12):2619–29.CrossRefPubMedPubMedCentral
54.
55.•
Cusano NE. Skeletal effects of smoking. Curr Osteoporos Rep. 2015;13(5):302–9. This paper discusses the significant negative impact of smoking, which has an increased prevalence amongst patients with schizophrenia, on bone health.CrossRefPubMed
56.
57.
Compston J et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62(2):105–8.CrossRefPubMed
58.
Shim J-C, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry. 2007
Metadata
Title
Lower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysis
Authors
Lucia Gomez
Brendon Stubbs
Ayala Shirazi
Davy Vancampfort
Fiona Gaughran
John Lally
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 6/2016
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-016-0325-0

Other articles of this Issue 6/2016

Current Osteoporosis Reports 6/2016 Go to the issue

Craniofacial Skeleton (G Roberts, Section Editor)

Recent Tissue Engineering Advances for the Treatment of Temporomandibular Joint Disorders

Bone and Diabetes (A Schwartz and P Vestergaard, Section Editors)

Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts

Craniofacial Skeleton (G Roberts, Section Editor)

Bone Response of Loaded Periodontal Ligament

Craniofacial Skeleton (E Roberts, Section Editor)

Osteoporosis and Periodontitis

Bone and Joint Pain (J McDougall and S Bain, Section Editors)

Emerging Targets for the Management of Osteoarthritis Pain

Craniofacial Skeleton (WE Roberts, Section Editor)

Bone Density and Dental External Apical Root Resorption